SCHEMBL3706219

SCHEMBL3706219

O=C(Nc1cc[c]cc1)c1cccc2nsnc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.49
▸ HPGD P15428 4/20 0.49
▸ HTT P42858 2/20 0.49
▸ ALDH1A1 P00352 8/20 0.49
▸ MAPT P10636 6/20 0.49
▸ NPC1 O15118 4/20 0.49
▸ RAB9A P51151 4/20 0.49
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ L3MBTL1 Q9Y468 3/20 0.49
▸ KDM4E B2RXH2 4/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ POLB P06746 2/20 0.45
▸ CTDSP1 Q9GZU7 2/20 0.45
▸ HSD17B10 Q99714 1/20 0.44
▸ ATM Q13315 1/20 0.43
▸ GAA P10253 1/20 0.41
▸ DUSP3 P51452 1/20 0.41
▸ PTPN5 P54829 1/20 0.41
▸ CASP6 P55212 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27586118 0.76 HPGD (0.49) SMN1; SMN2HPGDHTTALDH1A1MAPT
SCHEMBL12956408 0.74 L3MBTL1 (0.58) SMN1; SMN2HPGDHTTALDH1A1MAPT
SCHEMBL13234689 0.73 FLT3 (0.61) NPC1RAB9AMEN1KMT2A
SCHEMBL1338456 0.72 L3MBTL1 (0.61) SMN1; SMN2HPGDALDH1A1MAPTNPC1
SCHEMBL1019293 0.71 HPGD (0.49) SMN1; SMN2HPGDHTTALDH1A1MAPT
SCHEMBL14392300 0.71 KDM4E (0.53) SMN1; SMN2HPGDHTTALDH1A1MAPT
SCHEMBL12391731 0.70 POLB (0.51) HPGDALDH1A1MAPTRAB9AMEN1
SCHEMBL1870776 0.69 MEN1 (0.73) SMN1; SMN2HPGDHTTALDH1A1MAPT
SCHEMBL14223828 0.69 CTDSP1 (0.70) HTTALDH1A1MAPTMEN1KMT2A
SCHEMBL7125242 0.69 L3MBTL1 (0.70) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors AMGEN INC. (US) 2012-06-28 — — US claimed
EP-2398791-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS Amgen, Inc (US) 2011-12-28 — — EP claimed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 — — WO claimed
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors AMGEN INC. (US) 2012-06-28 — — US disclosed
EP-2398791-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS Amgen, Inc (US) 2011-12-28 — — EP disclosed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors MTOR, PIKFYVE, RICTOR SMN1; SMN2 3660/4885HPGD 2732/4885HTT 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback